The neuropeptide vasoactive intestinal peptide: Direct effects on immune cells and involvement in inflammatory and autoimmune diseases

Acta Physiologica

Volumn 213, Issue 2, 2015, Pages 442-452

  Ganea, D ^a   Hooper, K M ^a   Kong, W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune diseases; Innate immunity; Neuropeptides; T cell differentiation; Tolerogenic dendritic cells; Vasoactive intestinal peptide

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; NEUROPEPTIDE;

ADAPTIVE IMMUNITY; ARTHRITIS; AUTOIMMUNE DISEASE; CELL THERAPY; COLITIS; DENDRITIC CELL; GENE OVEREXPRESSION; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MICROGLIA; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY T LYMPHOCYTE; REVIEW; SARCOIDOSIS; TRANSGENICS; ANIMAL; INFLAMMATION; METABOLISM; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; NEUROPEPTIDES; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; T-LYMPHOCYTES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84920993336     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12427     Document Type: Review

References (99)

1. Abad, C., Tan, Y.V., Lopez, R., Nobuta, H., Dong, H., Phan, P., Feng, J.M., Campagnoni, A.T. & Waschek, J.A. 2010. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107, 19555-19560.
2. Abad, C., Tan, Y.V., Cheung-Lau, G., Nobuta, H. & Waschek, J.A. 2012. VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One 7, e36922.
3. Andersen, O., Fahrenkrug, J., Wikkelso, C. & Johansson, B.B. 1984. VIP in cerebrospinal fluid of patients with multiple sclerosis. Peptides 5, 435-437.
4. Arranz, A., Juarranz, Y., Leceta, J., Gomariz, R.P. & Martinez, C. 2008. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29, 948-956.
5. Aton, S.J., Colwell, C.S., Harmar, A.J., Waschek, J. & Herzog, E.D. 2005. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci 8, 476-483.
6. Bangale, Y., Karle, S., Planque, S., Zhou, Y.X., Taguchi, H., Nishiyama, Y., Li, L., Kalaga, R. & Paul, S. 2003. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J 17, 628-635.
7. Bellinger, D.L., Lorton, D., Brouxhon, S., Felten, S. & Felten, D.L. 1996. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 6, 5-27.
8. Bellinger, D.L., Lorton, D., Horn, L., Brouxhon, S., Felten, S.Y. & Felten, D.L. 1997. Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes. Peptides 18, 1139-1149.
9. Bloom, S.R., Polak, J.M. & Pearse, A.G. 1973. Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet 2, 14-16.
10. + regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131, 1853-1860.
11. + T regulatory cells. Scand J Immunol 68, 572-578.
12. Chorny, A. & Delgado, M. 2008. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172, 1297-1307.
13. Chorny, A., Gonzalez-Rey, E., Fernandez-Martin, A., Pozo, D., Ganea, D. & Delgado, M. 2005. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 102, 13562-13567.
14. Chorny, A., Gonzalez-Rey, E., Fernandez-Martin, A., Ganea, D. & Delgado, M. 2006. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 107, 3787-3794.
15. Chu, T.G. & Orlowski, M. 1985. Soluble metalloendopeptidase from rat brain: action on enkephalin-containing peptides and other bioactive peptides. Endocrinology 116, 1418-1425.
16. Colwell, C.S., Michel, S., Itri, J., Rodriguez, W., Tam, J., Lelievre, V., Hu, Z., Liu, X. & Waschek, J.A. 2003. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 285, R939-R949.
17. Delgado, M. 2002. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Biochem Biophys Res Commun 293, 771-776.
18. Delgado, M. & Ganea, D. 2000. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165, 3051-3057.
19. Delgado, M. & Ganea, D. 2001a. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol 166, 2907-2912.
20. Delgado, M. & Ganea, D. 2001b. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167, 966-975.
21. Delgado, M. & Ganea, D. 2001c. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276, 369-380.
22. Delgado, M. & Ganea, D. 2003a. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17, 944-946.
23. Delgado, M. & Ganea, D. 2003b. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun 301, 825-832.
24. Delgado, M. & Ganea, D. 2003c. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J 17, 1922-1924.
25. Delgado, M., Munoz-Elias, E.J., Kan, Y., Gozes, I., Fridkin, M., Brenneman, D.E., Gomariz, R.P. & Ganea, D. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem 273, 31427-31436.
26. Delgado, M., Sun, W., Leceta, J. & Ganea, D. 1999. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J Immunol 163, 4213-4223.
27. Delgado, M., Jonakait, G.M. & Ganea, D. 2002a. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39, 148-161.
28. Delgado, M., Leceta, J. & Ganea, D. 2002b. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16, 1844-1846.
29. Delgado, M., Gonzalez-Rey, E. & Ganea, D. 2004a. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 18, 1453-1455.
30. Delgado, M., Pozo, D. & Ganea, D. 2004b. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56, 249-290.
31. Delgado, M., Reduta, A., Sharma, V. & Ganea, D. 2004c. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol 75, 1122-1130.
32. + regulatory T cells in vivo. J Leukoc Biol 78, 1327-1338.
33. Delgado, M., Gonzalez-Rey, E. & Ganea, D. 2005b. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 175, 7311-7324.
34. Delgado, M., Robledo, G., Rueda, B., Varela, N., O'Valle, F., Hernandez-Cortes, P., Caro, M., Orozco, G., Gonzalez-Rey, E. & Martin, J. 2008a. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum 58, 1010-1019.
35. Delgado, M., Toscano, M.G., Benabdellah, K., Cobo, M., O'Valle, F., Gonzalez-Rey, E. & Martin, F. 2008b. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum 58, 1026-1037.
36. Delgado, M., Varela, N. & Gonzalez-Rey, E. 2008c. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 56, 1091-1103.
37. Deng, S., Xi, Y., Wang, H., Hao, J., Niu, X., Li, W., Tao, Y. & Chen, G. 2010. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 265, 105-110.
38. Dickson, L. & Finlayson, K. 2009. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121, 294-316.
39. Ding, W., Manni, M., Stohl, L.L., Zhou, X.K., Wagner, J.A. & Granstein, R.D. 2012. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol 42, 901-911.
40. Fernandez-Martin, A., Gonzalez-Rey, E., Chorny, A., Martin, J., Pozo, D., Ganea, D. & Delgado, M. 2006. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann N Y Acad Sci 1070, 276-281.
41. Ferraccioli, G. & Zizzo, G. 2011. The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discov Med 11, 413-424.
42. Foster, N., Lea, S.R., Preshaw, P.M. & Taylor, J.J. 2007. Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 81, 893-903.
43. Fry, D.C., Madison, V.S., Bolin, D.R., Greeley, D.N., Toome, V. & Wegrzynski, B.B. 1989. Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics. Biochemistry 28, 2399-2409.
44. Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T. & Fujiyama, Y. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70.
45. Ganea, Da.M.S. 2013. Immunoregulatory neuropeptides. In: A.W. Kusnecov & H. Anisman (eds). The Wiley-Blackwell Handbook of Psychoneuroimmunology, pp. 144-160. Wiley-Blackwell, London.
46. Ganea, D., Rodriguez, R. & Delgado, M. 2003. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol (Noisy-le-Grand) 49, 127-142.
47. Goetzl, E.J., Voice, J.K., Shen, S., Dorsam, G., Kong, Y., West, K.M., Morrison, C.F. & Harmar, A.J. 2001. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 98, 13854-13859.
48. Gomariz, R.P., Arranz, A., Abad, C., Torroba, M., Martinez, C., Rosignoli, F., Garcia-Gomez, M., Leceta, J. & Juarranz, Y. 2005. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 78, 491-502.
49. Gonzalez-Rey, E. & Delgado, M. 2007. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci 28, 482-491.
50. + T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 54, 864-876.
51. Gonzalez-Rey, E., Fernandez-Martin, A., Chorny, A., Martin, J., Pozo, D., Ganea, D. & Delgado, M. 2006b. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168, 1179-1188.
52. Gonzalez-Rey, E., Ganea, D. & Delgado, M. 2010. Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Curr Opin Pharmacol 10, 473-481.
53. Gozes, I., Glowa, J., Brenneman, D.E., McCune, S.K., Lee, E. & Westphal, H. 1993. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J Mol Neurosci 4, 185-193.
54. Gutierrez-Canas, I., Juarranz, Y., Santiago, B., Arranz, A., Martinez, C., Galindo, M., Paya, M., Gomariz, R.P. & Pablos, J.L. 2006. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) 45, 527-532.
55. Hamidi, S.A., Szema, A.M., Lyubsky, S., Dickman, K.G., Degene, A., Mathew, S.M., Waschek, J.A. & Said, S.I. 2006. Clues to VIP function from knockout mice. Ann N Y Acad Sci 1070, 5-9.
56. Hauk, V., Fraccaroli, L., Grasso, E., Eimon, A., Ramhorst, R., Hubscher, O. & Perez Leiros, C. 2014. Monocytes from Sjogren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis. Clin Exp Immunol 177, 662-670.
57. Henning, R.J. & Sawmiller, D.R. 2001. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 49, 27-37.
58. Jiang, X., Jing, H. & Ganea, D. 2002. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol 133, 81-94.
59. Jimeno, R., Gomariz, R.P., Gutierrez-Canas, I., Martinez, C., Juarranz, Y. & Leceta, J. 2010. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 88, 734-745.
60. Jimeno, R., Leceta, J., Martinez, C., Gutierrez-Canas, I., Carrion, M., Perez-Garcia, S., Garin, M., Mellado, M., Gomariz, R.P. & Juarranz, Y. 2014. Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells. J Mol Neurosci 54, 512-525.
61. Juarranz, Y., Gutierrez-Canas, I., Santiago, B., Carrion, M., Pablos, J.L. & Gomariz, R.P. 2008. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58, 1086-1095.
62. Kanellopoulos-Langevin, C., Caucheteux, S.M., Verbeke, P. & Ojcius, D.M. 2003. Tolerance of the fetus by the maternal immune system: role of inflammatory mediators at the feto-maternal interface. Reprod Biol Endocrinol 1, 121.
63. Kato, I., Suzuki, Y., Akabane, A., Yonekura, H., Tanaka, O., Kondo, H., Takasawa, S., Yoshimoto, T. & Okamoto, H. 1994. Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic beta cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo. J Biol Chem 269, 21223-21228.
64. Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B. & Prat, A. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13, 1173-1175.
65. Kim, W.K., Kan, Y., Ganea, D., Hart, R.P., Gozes, I. & Jonakait, G.M. 2000. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci 20, 3622-3630.
66. Lampron, A., Elali, A. & Rivest, S. 2013. Innate immunity in the CNS: redefining the relationship between the CNS and Its environment. Neuron 78, 214-232.
67. Lauenstein, H.D., Quarcoo, D., Plappert, L., Schleh, C., Nassimi, M., Pilzner, C., Rochlitzer, S., Brabet, P., Welte, T., Hoymann, H.G., Krug, N., Muller, M., Lerner, E.A., Braun, A. & Groneberg, D.A. 2010. Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice. Clin Exp Allergy 41, 592-601.
68. Lauenstein, H.D., Quarcoo, D., Plappert, L., Schleh, C., Nassimi, M., Pilzner, C., Rochlitzer, S., Brabet, P., Welte, T., Hoymann, H.G., Krug, N., Muller, M., Lerner, E.A., Braun, A. & Groneberg, D.A. 2011. Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice. Clin Exp Allergy 41, 592-601.
69. Leceta, J., Martinez, M.C., Delgado, M., Garrido, E. & Gomariz, R.P. 1994. Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. Peptides 15, 791-797.
70. Lee, Y., Awasthi, A., Yosef, N., Quintana, F.J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D.A., Sobel, R.A., Regev, A. & Kuchroo, V.K. 2012. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13, 991-999.
71. Lelievre, V., Favrais, G., Abad, C., Adle-Biassette, H., Lu, Y., Germano, P.M., Cheung-Lau, G., Pisegna, J.R., Gressens, P., Lawson, G. & Waschek, J.A. 2007. Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 28, 1688-1699.
72. Leuchte, H.H., Baezner, C., Baumgartner, R.A., Bevec, D., Bacher, G., Neurohr, C. & Behr, J. 2008. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32, 1289-1294.
73. Li, J.M., Southerland, L., Hossain, M.S., Giver, C.R., Wang, Y., Darlak, K., Harris, W., Waschek, J. & Waller, E.K. 2011. Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. J Immunol 187, 1057-1065.
74. Liu, L., Yen, J.H. & Ganea, D. 2007. A novel VIP signaling pathway in T cells cAMP->protein tyrosine phosphatase (SHP-2?)->JAK2/STAT4->Th1 differentiation. Peptides 28, 1814-1824.
75. Maldonado, R.A. & von Andrian, U.H. 2010. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108, 111-165.
76. Martinez, C., Delgado, M., Pozo, D., Leceta, J., Calvo, J.R., Ganea, D. & Gomariz, R.P. 1998. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol 85, 155-167.
77. Martinez, C., Abad, C., Delgado, M., Arranz, A., Juarranz, M.G., Rodriguez-Henche, N., Brabet, P., Leceta, J. & Gomariz, R.P. 2002. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA 99, 1053-1058.
78. Martinez, C., Ortiz, A.M., Juarranz, Y., Lamana, A., Seoane, I.V., Leceta, J., Garcia-Vicuna, R., Gomariz, R.P. & Gonzalez-Alvaro, I. 2014. Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. PLoS One 9, e85248.
79. Morice, A., Unwin, R.J. & Sever, P.S. 1983. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2, 1225-1227.
80. Ousman, S.S. & Kubes, P. 2012. Immune surveillance in the central nervous system. Nat Neurosci 15, 1096-1101.
81. Paladini, F., Cocco, E., Cauli, A., Cascino, I., Vacca, A., Belfiore, F., Fiorillo, M.T., Mathieu, A. & Sorrentino, R. 2008. A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia. Genes Immun 9, 659-667.
82. Prasse, A., Zissel, G., Lutzen, N., Schupp, J., Schmiedlin, R., Gonzalez-Rey, E., Rensing-Ehl, A., Bacher, G., Cavalli, V., Bevec, D., Delgado, M. & Muller-Quernheim, J. 2010. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 182, 540-548.
83. Ransohoff, R.M. & Brown, M.A. 2012. Innate immunity in the central nervous system. J Clin Invest 122, 1164-1171.
84. Samarasinghe, A.E., Hoselton, S.A. & Schuh, J.M. 2011. The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice. Peptides 32, 131-137.
85. Sanlioglu, S. 2014. Vasoactive intestinal peptide-mediated gene therapy for diabetes. JOP 15, 2783.
86. Sharma, V., Delgado, M. & Ganea, D. 2006. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 176, 97-110.
87. Sharpless, N.S., Thal, L.J., Perlow, M.J., Tabaddor, K., Waltz, J.M., Shapiro, K.N., Amin, I.M., Engel, J. Jr & Crandall, P.H. 1984. Vasoactive intestinal peptide in cerebrospinal fluid. Peptides 5, 429-433.
88. Shen, S., Spratt, C., Sheward, W.J., Kallo, I., West, K., Morrison, C.F., Coen, C.W., Marston, H.M. & Harmar, A.J. 2000. Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. Proc Natl Acad Sci USA 97, 11575-11580.
89. Stein-Streilein, J. & Caspi, R.R. 2014. Immune privilege and the philosophy of immunology. Front Immunol 5, 110.
90. Sun, W., Hong, J., Zang, Y.C., Liu, X. & Zhang, J.Z. 2006. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 18, 1691-1700.
91. Szema, A.M., Hamidi, S.A., Golightly, M.G., Rueb, T.P. & Chen, J.J. 2011. VIP Regulates the Development & Proliferation of Treg in vivo in spleen. Allergy Asthma Clin Immunol 7, 19.
92. Tan, Y.V., Abad, C., Lopez, R., Dong, H., Liu, S., Lee, A., Gomariz, R.P., Leceta, J. & Waschek, J.A. 2009. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 106, 2012-2017.
93. Toscano, M.G., Delgado, M., Kong, W., Martin, F., Skarica, M. & Ganea, D. 2010. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 18, 1035-1045.
94. Voice, J.K., Dorsam, G., Lee, H., Kong, Y. & Goetzl, E.J. 2001. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J 15, 2489-2496.
95. Voice, J.K., Grinninger, C., Kong, Y., Bangale, Y., Paul, S. & Goetzl, E.J. 2003. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 170, 308-314.
96. Voice, J., Donnelly, S., Dorsam, G., Dolganov, G., Paul, S. & Goetzl, E.J. 2004. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 172, 7289-7296.
97. Yadav, M., Rosenbaum, J. & Goetzl, E.J. 2008. Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 180, 2772-2776.
98. Yadav, M., Huang, M.C. & Goetzl, E.J. 2011. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol 267, 124-132.
99. Zhao, S., Zhu, W., Xue, S. & Han, D. 2014. Testicular defense systems: immune privilege and innate immunity. Cell Mol Immunol 11, 428-437.